全文获取类型
收费全文 | 6121篇 |
免费 | 409篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 109篇 |
妇产科学 | 93篇 |
基础医学 | 599篇 |
口腔科学 | 116篇 |
临床医学 | 668篇 |
内科学 | 1303篇 |
皮肤病学 | 55篇 |
神经病学 | 482篇 |
特种医学 | 512篇 |
外科学 | 954篇 |
综合类 | 97篇 |
一般理论 | 2篇 |
预防医学 | 647篇 |
眼科学 | 81篇 |
药学 | 332篇 |
1篇 | |
中国医学 | 5篇 |
肿瘤学 | 444篇 |
出版年
2021年 | 82篇 |
2020年 | 52篇 |
2019年 | 80篇 |
2018年 | 118篇 |
2017年 | 75篇 |
2016年 | 74篇 |
2015年 | 97篇 |
2014年 | 137篇 |
2013年 | 200篇 |
2012年 | 351篇 |
2011年 | 327篇 |
2010年 | 169篇 |
2009年 | 151篇 |
2008年 | 271篇 |
2007年 | 304篇 |
2006年 | 270篇 |
2005年 | 266篇 |
2004年 | 268篇 |
2003年 | 210篇 |
2002年 | 199篇 |
2001年 | 180篇 |
2000年 | 194篇 |
1999年 | 161篇 |
1998年 | 57篇 |
1997年 | 43篇 |
1996年 | 51篇 |
1995年 | 47篇 |
1994年 | 50篇 |
1993年 | 47篇 |
1992年 | 153篇 |
1991年 | 132篇 |
1990年 | 160篇 |
1989年 | 149篇 |
1988年 | 144篇 |
1987年 | 137篇 |
1986年 | 130篇 |
1985年 | 104篇 |
1984年 | 90篇 |
1983年 | 74篇 |
1982年 | 45篇 |
1980年 | 39篇 |
1979年 | 56篇 |
1978年 | 60篇 |
1977年 | 37篇 |
1976年 | 38篇 |
1974年 | 52篇 |
1973年 | 46篇 |
1972年 | 44篇 |
1970年 | 38篇 |
1969年 | 38篇 |
排序方式: 共有6554条查询结果,搜索用时 265 毫秒
81.
Melody R. Palmer Daniel S. Kim David R. Crosslin Ian B. Stanaway Elisabeth A. Rosenthal David S. Carrell David J. Cronkite Adam Gordon Xiaomeng Du Yatong K. Li Marc S. Williams Chunhua Weng Qiping Feng Rongling Li Sarah A. Pendergrass Hakon Hakonarson David Fasel Sunghwan Sohn Patrick Sleiman Samuel K. Handelman Elizabeth Speliotes Iftikhar J. Kullo Eric B. Larson Gail P. Jarvik 《Genetic epidemiology》2021,45(1):4-15
82.
D L Larson 《Clinics in plastic surgery》1990,17(3):509-517
Though uncommon, the occurrence of an extravasation of a tissue-toxic drug can be a very disconcerting event in the physician's practice. A wound specialist, such as a plastic surgeon, is frequently consulted. The author reviews the "state of the art" approach to these challenging wounds. 相似文献
83.
Nilsson S Essand M Logdahl P Larson A Nordgren H Juhlin C 《Cancer biotherapy & radiopharmaceuticals》1997,12(6):395-403
The monoclonal antibody E4 (IgG2a, kappa) was raised by immunizing mice with dispersed cells obtained from human benign prostatic hyperplasia (BPH). The antibody identifies an antigen abundantly expressed in normal prostate epithelial cells, in benign epithelial prostatic cells and in well- and moderately well differentiated adenocarcinomas of the prostate, whereas poorly differentiated prostatic adenocarcinomas display somewhat less expression. Investigation of the human prostatic adenocarcinoma cell line DU 145 revealed E4 immunoreactivity localized to the cell surface. SDS-PAGE analysis under reducing conditions demonstrated an approximate molecular weight of 70,000 for the antigen. The highly specific reactivity with prostate tissue, as well as intense surface staining, especially in well- and moderately well differentiated prostatic adenocarcinomas, makes the E4 antibody a useful immunohistochemical marker and a possible candidate for future immunoscintigraphy and/or targeted radiotherapy. 相似文献
84.
Kathryn Lauer Charul Munshi Sanford Larson 《Journal of clinical monitoring and computing》1994,10(3):181-184
Objective. To quantify the effect of an induction dose of midazolam on median nerve somatosensory evoked potentials.Methods. We studied 10 patients undergoing lumbar spine surgery. After an induction dose of intravenous midazolam was given, MNEPs were collected for ten minutes. After ten minutes the patients were intubated and their anesthetic was supplemented with 0.5% isoflurane, narcotic, and N2O.Results. We found a clinically significant decrease in amplitude and an insignificant delay in latency.Conclusion. When midazolam is used as an anesthetic induction agent, a decrease in amplitude can be expected. 相似文献
85.
86.
87.
88.
89.
90.
H Preisler A Raza R Larson J Goldberg G Tricot M Carey C Kukla 《Leukemia research》1991,15(9):773-780
The failure of three consecutive treatment protocols to significantly increase the complete remission rate for poor prognosis newly diagnosed patients with acute myelocytic leukemia led to a detailed investigation of the causes of treatment failure. In the majority of cases treatment failure was attributable to "clinical resistance" to therapy. Upon close examination two types of "clinical resistance" were discernible: the failure of chemotherapy to produce adequate cytotoxic effects ("classical" drug resistance), and treatment failure attributed to the rapid regrowth of leukemia cells subsequent to the substantial killing of leukemia cells by cytotoxic therapy ("biological" resistance). Each form of resistance accounted for one-half of the treatment failures. 相似文献